Devnandan Chatterjee

Dr. Devnandan Chatterjee

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
KKKonstantin Kazankov
Konstantin Kazankov
SNSimone Novelli
Simone Novelli
DCDevnandan Chatterjee
Devnandan Chatterjee
APAlexandra Phillips
Alexandra Phillips
ABAnu Balaji
Anu Balaji
RMRajeshwar P. Mookerjee
Rajeshwar P. Mookerjee

8 July 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CJChristian Jansen
Christian Jansen
DCDevnandan Chatterjee
Devnandan Chatterjee
KTKaren Louise Thomsen
Karen Louise Thomsen
BABaravan Al‐Kassou
Baravan Al‐Kassou
RSRohit Sawhney
Rohit Sawhney
RMRajeshwar P. Mookerjee
Rajeshwar P. Mookerjee
Summary: Background: Heart rate variability (HRV) is reduced in cirrhosis and in conditions of systemic inflammation. Whether HRV is associated with cirrhosis decompensation and development of acute‐on‐chronic liver failure (ACLF) is unknown.Aims: To (a) validate wireless remote HRV monitoring in cirrhosis decompensation; (b) determine if severely reduced HRV is a surrogate for inflammation and progression of cirrhosis decompensation; (c) assess if measuring HRV determines prognosis in cirrhosis decompensation.Methods: One hundred and eleven patients at risk of cirrhosis decompensation at two clinical sites were monitored for HRV. Standard deviation of all normal beat‐beat intervals (SDNN) reflecting HRV was assessed using remote monitoring (Isansys Lifetouch) and/or Holter ECG recording. Clinical outcomes and major prognostic scores were recorded during 90‐day follow‐up.Results: Reduced HRV denoted by lower baseline SDNN, correlated with severity of decompensation (median 14 (IQR 11‐23) vs 33 (25‐42); P < 0.001, decompensated patients vs stable outpatient cirrhosis). Furthermore, SDNN was significantly lower in patients developing ACLF compared to those with only decompensation (median 10 (IQR9‐12) vs 16 (11‐24); P = 0.02), and correlated inversely with MELD and Child‐Pugh scores, and C‐reactive protein (all P < 0.0001) and white cell count (P < 0.001). SDNN predicted disease progression on repeat measures and appeared an independent predictor of 90‐day mortality (12 patients). An SDNN cut‐off of 13.25 ms had a 98% negative predictive value.Conclusions: This study demonstrates that remote wireless HRV monitoring identifies cirrhosis patients at high risk of developing ACLF and death, and suggests such monitoring might guide the need for early intervention in such patients. Clinical Trial number: NIHR clinical research network CPMS ID 4949.

Verified
Journal Article
Open access
PDF file
MBMegan Bannister
Megan Bannister
DCDevnandan Chatterjee
Devnandan Chatterjee
SSShishir Shetty
Shishir Shetty
DPDaniel Patten
Daniel Patten
Hepatocellular carcinoma (HCC) represents a significant clinical burden globally and is predicted to continue to increase in incidence for the foreseeable future. The treatment of HCC is complicated by the fact that, in the majority of cases, it develops on a background of advanced chronic inflammatory liver disease. Chronic inflammation can foster an immunosuppressive microenvironment that promotes tumour progression and metastasis. In this setting, macrophages make up a major immune component of the HCC tumour microenvironment, and in this review, we focus on their contribution to HCC development and progression. Tumour-associated macrophages (TAMs) are largely derived from infiltrating monocytes and their potent anti-inflammatory phenotype can be induced by factors that are found within the tumour microenvironment, such as growth factors, cytokines, hypoxia, and extracellular matrix (ECM) proteins. In general, experimental evidence suggest that TAMs can exhibit a variety of functions that aid HCC tumour progression, including the promotion of angiogenesis, resistance to drug therapy, and releasing factors that support tumour cell proliferation and metastasis. Despite their tumour-promoting profile, there is evidence that the underlying plasticity of these cells can be targeted to help reprogramme TAMs to drive tumour-specific immune responses. We discuss the potential for targeting TAMs therapeutically either by altering their phenotype within the HCC microenvironment or by cell therapy approaches by taking advantage of their infiltrative properties from the circulation into tumour tissue.

9 June 2014 in Gut
Verified
Journal Article
Open access
PDF file
DCDevnandan Chatterjee
Devnandan Chatterjee
HJHe Jones
He Jones
ALAg León
Ag León
GPG Privitera
G Privitera
RJR Jalan
R Jalan
RMRp Mookerjee
Rp Mookerjee
Introduction: Hospital readmission from inter-current illness is common in advanced cirrhosis. Community monitoring of these patients with simple information-based technology may facilitate early problem recognition and intervention. Heart rate variability (HRV) has been deemed the ‘gold standard’ tool to characterise autonomic dysfunction, which is widely reported in cirrhosis, and remains independent of aetiology, and its severity has been shown to correlate with prognosis. However, the methods to study continuous measurement of HRV and studies in advanced cirrhosis are limited. Aims: This study used a wireless-monitoring technology, Lifetouch® system (Isansys), to assess changes of HRV remotely in acute-on-chronic liver failure (ACLF) patients, and evaluated the relationship to the severity of disease and inflammatory indices. Methods: Following ethical and local site approval, nineteen patients (13 male/6 female; mean age 52.5 ± 12.0 years) had HRV assessment following presentation to The Royal Free hospital, using the Lifetouch ® system, with the standard deviation of the R-R interval (SDNN) used to collect changes in HRV. This novel system enabled continuous, wireless evaluation of HRV, which was compared with clinical, biochemical and inflammatory indices (IL-6, IL-8 and IL-10 measured by multiplex cytokine analysis). Results: HRV, as determined by SDNN, was significantly greater in cirrhosis patients with Child-Pugh scores 10 (31.26 ± 14.90 vs. 10.80 ± 5.61 ms). Similarly, UKELD correlated inversely with SDNN (R 2 = -0.46; p < 0.01). Spearman’s rank analysis of SDNN in relation to the inflammatory indices: WCC, CRP, IL-6, IL-8 and IL-10 levels were -0.60 (p = 0.01), -0.56 (p = 0.01), -0.77 (p = 0.02), -0.86 (p = 0.01) and -0.79 (p = 0.04), respectively. Using a SDNN cut-off of ≤20 ms to signify patients with advanced disease (Child C), all inflammatory indices were shown to be significantly increased (P < 0.01). Conclusion: This pilot study provides proof of concept that remote monitoring showing reduced HRV, identifies patients with increased inflammation, more advanced liver disease and those most likely to present with acute decompensation of cirrhosis. Further study and refinement of this system may facilitate community monitoring of advanced liver disease patients, to provide ‘alarm’ signals that highlight acute decompensation and precipitate early intervention care pathways. Disclosure of Interest: None Declared.

1 January 2019 in Kidney International
Verified
Journal Article
Closed access
LELucy Everson
Lucy Everson
BBBrett Sydney Bernstein
Brett Sydney Bernstein
DCDevnandan Chatterjee
Devnandan Chatterjee
BLBen Lindsey
Ben Lindsey
FMFiona McCaig
Fiona McCaig
ASAlan D. Salama
Alan D. Salama